This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

This Relative Strength Play Is Ready to Pop

 DELAFIELD, Wis. (Stockpickr) -- U.S. stocks are struggling to gain any traction on Tuesday after the Commerce Department said the trade gap narrowed in March by 3.6% to $40.4 billion, which was basically in line with economists' expectations.

>>5 Hated Earnings Stocks You Should Love

All three major averages are trending lower midday, with the Dow Jones Industrial Average off by around 75 points, the S&P 500 down by 7 points and the tech-heavy Nasdaq trending lower by around 20 points.

On down days like today, I like to scan the markets for stocks that aren't going down and that are showing some relative strength. Relative strength is a momentum investing strategy that compares the performance of a stock to that of the overall market. The strategy assumes that if a stock is rising while the market is falling, then that stock should see its price continue to rise.

Must Read: 5 Hated Earnings Stocks You Should Love

One stock that's showing some relative strength today and that has some positive news flow is mid-cap biotechnology player InterMune (ITMN), which focuses on the research, development and commercialization of therapies for pulmonology and orphan fibrotic diseases in North America and Europe. This biotech stock has been incredibly strong so far in 2014, with shares up huge by 192%.

>>4 Stocks Spiking on Big Volume

InterMune recently reported earnings and said year-over-year sales during the first quarter for its lead drug, Esbriet, a treatment for idiopathic pulmonary fibrosis, were very strong. Those sales jumped by 188% during the quarter to $30.3 million, from $10.5 million in the year-ago period. Based on those strong results, InterMune raised its 2014 revenue guidance to a range of $130 million to $140 million. That jump in guidance now puts the potential revenue growth for Esbriet at 85% to 100% from its 2013 revenue of $70.3 million. That's some monster growth, and the market will be sure to reward InterMune if the company can hit those targets.

InterMune plans to resubmit its application for Esbriet with the FDA in the U.S. sometime in the early part of the third quarter. If the company can achieve FDA approval, then the planned launch for the drug in the U.S. should hit sometime during the second quarter of 2015.

The recent strong earnings news for InterMune is a nice backdrop for the stock, but the bullish news flow today comes from a number of analysts' comments. One report suggests the company could potentially be acquired in a few months, according to Another report from Oppenheimer says the stock should be bought ahead of the American Thoracic Society meeting that's slated for later this month. Oppenheimer also said it met with three leading experts who believe that Esbriet is significantly more tolerable than a competing drug.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
ITMN $73.89 -0.03%
AAPL $93.25 0.01%
FB $117.80 -0.01%
GOOG $704.04 0.37%
TSLA $211.84 0.15%


Chart of I:DJI
DOW 17,648.97 -11.74 -0.07%
S&P 500 2,048.63 -2.00 -0.10%
NASDAQ 4,709.3430 -7.7510 -0.16%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs